

THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER



HLC143A
June 2013

Usha Nagavarapu
Project Analyst

ISBN: 1-56965-431-X

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR CONDUCTING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	4
RELATED BCC REPORTS	4
BCC ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, 2012-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	9
OVARIAN CANCERS	9
<i>TABLE 1 OVARIAN CANCER FACTS</i>	9
<i>TABLE 2 TYPES OF OVARIAN CANCERS</i>	10
EPITHELIAL TUMORS	10
GERM CELL TUMORS	10
STROMAL TUMORS	10
METASTASIS	10
<i>TABLE 3 OVARIAN TUMORS METASTASIS</i>	11
OVARIAN DISORDERS	11
RISK FACTORS	11
<i>TABLE 4 MAIN RISK FACTORS FOR OVARIAN CANCER</i>	12
<i>TABLE 5 HIGH-RISK FACTORS</i>	12
PREVENTION	13
<i>TABLE 6 PREVENTIVE FACTORS</i>	13
PREVENTIVE STRATEGIES FOR HIGH-RISK WOMEN	13
SYMPTOMS	14
<i>TABLE 7 OVARIAN CANCER SYMPTOMS</i>	14
SIGNS OF CANCER	15
DIAGNOSIS AND SYMPTOM PROGRESSION	15
Early Detection	16
DIAGNOSIS	16
TUMOR MARKERS	16
VITAMIN D AND OVARIAN CANCER	16
PROGNOSIS	17
PROGNOSIS BY STAGE	17
TREATMENT	17
CHEMOTHERAPY	18

TOPIC	PAGE NO.
TARGETED THERAPY	18
IMMUNOTHERAPY	18
RESEARCH AND NEW DEVELOPMENTS	18
CONCLUSIONS	19
CHAPTER 4 OVARIAN CANCER: BIOLOGY	21
OVERVIEW	21
REPRODUCTIVE BIOLOGY	21
<i>TABLE 8 HOW OVARIAN CANCER CAN PROGRESS</i>	21
<i>TABLE 9 COMMON HISTOLOGICAL SUBTYPES OF OVARIAN CANCERS</i>	22
<i>TABLE 10 OVARIAN CANCER ORIGINS</i>	23
BORDERLINE TUMORS OF THE OVARY	24
BIOMARKERS	24
MOLECULAR ANALYSIS IN OVARIAN CANCER	25
<i>TABLE 11 MUTATED GENES IN HIGH-GRADE SEROUS OVARIAN CANCER</i>	25
Mutations and Different Subtypes of Ovarian Cancer	26
Potential Biomarkers and Mutations for Ovarian Cancer	26
Biomarkers and Future	27
Ovarian Cancer Biomarkers: Potential Use	27
Combining CA-125 with Other Biomarkers	28
Prognostic Biomarkers	28
<i>TABLE 12 GLOBAL PROGNOSTIC OVARIAN CANCER BIOMARKERS</i>	28
Novel Biomarkers	29
<i>TABLE 13 ACOG GUIDELINES 2002</i>	30
UPDATED ACOG GUIDELINES	31
CA-125: A QUESTION OF USE	31
DIAGNOSTIC TESTS BASED ON BIOMARKERS	31
MODIFIED ACOG REFERRAL GUIDELINES	32
A PROMISING CANDIDATE	32
HE4 AND THE ALGORITHM FOR RISK OF OVARIAN MALIGNANCY	33
OVA1 VERSUS ROMA	33
OVARIAN CANCER AND STEM CELLS	34
<i>TABLE 14 GENES IN TYPE I EPITHELIAL OVARIAN CANCER CELLS</i>	34
CONCLUSIONS	35
CHAPTER 5 OVARIAN CANCER DIAGNOSIS	37
CURRENT PRACTICES	37
PREVENTION	37
SYMPTOMS AND DIAGNOSIS	37
<i>TABLE 15 OVARIAN CANCER SYMPTOMS</i>	38
DIAGNOSIS	38
TUMOR MARKERS	39
CA-125	39
INITIAL SURGERY	39
EXPLORATORY LAPAROTOMY	39
PROGNOSIS	40
COMPLETE RESPONSE	40

TOPIC	PAGE NO.
RECURRENCE	41
MINIMALLY-INVASIVE PROCEDURE	41
ROUTINE OVARIAN CANCER SCREENING	41
STAGING	42
<i>TABLE 16 STAGES OF OVARIAN CANCER</i>	42
<i>TABLE 17 STAGING OF OVARIAN CANCER</i>	43
OVARIAN CANCER GRADING	43
OVARIAN CANCER DIAGNOSIS	44
PHYSICAL EXAM	44
PELVIC EXAM	44
<i>TABLE 18 DIAGNOSTIC TESTS FOR OVARIAN CANCER</i>	44
BLOOD TESTS	44
ULTRASOUND	44
BIOPSY	45
IMAGING STUDIES	45
ULTRASOUND	45
COMPUTED TOMOGRAPHY	46
BARIUM ENEMA X-RAY	46
MAGNETIC RESONANCE IMAGING	46
CHEST X-RAY	47
POSITRON EMISSION TOMOGRAPHY (PET SCAN)	47
OTHER TESTS	47
LAPAROSCOPY	47
COLONOSCOPY	47
BIOPSY	48
BIOMARKERS AND TESTS	48
RISK OF OVARIAN MALIGNANCY ALGORITHM	48
BLOOD TESTS	48
CA-125 BLOOD TEST	49
CA-125 Test to Monitor the Status of Ovarian Cancer	51
OTHER BIOMARKER-BASED BLOOD SCREENING TESTS FOR OVARIAN CANCER	51
<i>TABLE 19 TUMOR BIOMARKER-BASED TESTS FOR OVARIAN CANCER DIAGNOSIS</i>	51
HE4 BLOOD TEST	51
THE RISK OF OVARIAN MALIGNANCY ALGORITHM (ROMA) TEST	52
<i>TABLE 20 TEST FEATURES OF ROMA</i>	54
OVA1 TEST	55
OVADX	55
<i>TABLE 21 OVADX FEATURES</i>	56
GENETIC TESTING	56
NOVEL TEST PREDICTED PRESENCE OF BRCA MUTATIONS	57
SECOND TEST	57
Decision Tool for Women with BRCA Mutations	58
CURRENT SCREENING METHODS	58
NEED FOR A SCREENING STRATEGY	59
TO SCREEN OR NOT TO SCREEN	60
NEW DIAGNOSTIC TESTS	61

TOPIC	PAGE NO.
CHAPTER 6 TREATMENT STRATEGIES FOR OVARIAN CANCER	64
CURRENT TREATMENT PRACTICES	64
MAJOR MARKETED PRODUCTS	65
<i>TABLE 22 DRUGS FOR OVARIAN CANCER</i>	65
<i>TABLE 23 OTHER MAJOR THERAPEUTIC AGENTS</i>	65
SURGERY	66
<i>TABLE 24 CURRENT TREATMENT STRATEGY: OVARIAN CANCER</i>	66
CHEMOTHERAPY	67
Intraperitoneal Chemotherapy	69
<i>TABLE 25 CHEMOTHERAPEUTIC DRUGS FOR OVARIAN CANCER</i>	69
IV Chemotherapy	69
<i>TABLE 26 CHEMOTHERAPY ADMINISTRATION</i>	70
Side Effects	70
TARGETED THERAPY	70
IMMUNOTHERAPY	71
STAGING	71
TREATMENT OF OVARIAN EPITHELIAL CANCER	71
Stage I	71
<i>TABLE 27 TREATMENT OPTIONS BY STAGE</i>	72
Stage II	72
Stage III	72
Stage IV	72
RADIATION THERAPY	73
PALLIATIVE/SUPPORTIVE CARE	73
RECURRENT OVARIAN CANCER	73
METASTATIC OVARIAN CANCER	74
OVARIAN CANCER DRUGS PIPELINE	74
<i>TABLE 28 PIPELINE DRUG CLASSES</i>	74
<i>TABLE 29 OVARIAN CANCER DRUGS: DELIVERY TECHNOLOGIES</i>	75
SURVEILLANCE AFTER TREATMENT	75
<i>TABLE 30 OPTIMAL SURVEILLANCE STRATEGY</i>	75
RECURRENT OVARIAN EPITHELIAL CANCER	75
SECOND-LOOK SURGERY	76
TREATMENT OF RECURRENT CANCER	76
<i>TABLE 31 TREATMENT PLAN FOR RECURRENT CANCER</i>	76
MULTIDRUG RESISTANCE	77
<i>TABLE 32 PLATINUM RESISTANCE</i>	77
<i>TABLE 33 REASONS FOR THE ONSET OF MDR</i>	78
TREATMENT OF SENSITIVE CANCER	79
TREATMENT OF RESISTANT CANCER	79
SECONDARY-CHEMOTHERAPY DRUGS	80
TOPOTECAN	80
SINGLE-AGENT ETOPOSIDE	80
DOCETAXEL	81
GEMCITABINE	81
OXALIPLATIN	82
5-FU AND LEUCOVORIN	83

TOPIC	PAGE NO.
LIPOSOMAL DOXORUBICIN	83
HIGH-DOSE CHEMOTHERAPY	84
DRUGS APPROVED FOR OVARIAN CANCER	84
<i>TABLE 34 DRUGS APPROVED FOR OVARIAN CANCER</i>	84
PROMISING NEW THERAPIES	85
AVASTIN	85
<i>TABLE 35 NEW OVARIAN CANCER DRUGS</i>	85
DRUG THERAPIES IN CLINICAL TRIALS	86
<i>TABLE 36 OVARIAN CANCER DRUGS IN CLINICAL TRIALS</i>	86
BEVACIZUMAB AND RECURRENT OVARIAN CANCER	87
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients	87
PARP INHIBITORS	88
FUTURE TACTICS: THE ROLE OF BIOMARKERS	88
MOLECULAR THERAPEUTICS PROGRAM	89
BRCA1/2 ONCOGENES	89
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)	90
The EGFR/ErbB Family of Receptor Tyrosine Kinases	90
MUCIN 16 (MUC16)	91
LEWIS X MUCIN DETERMINANT (OVX1)	91
IL-6R-JAK-STAT3 AXIS AND NUCLEAR FACTOR KAPPA-B (NF-KB)	91
PI3K/AKT/MTOR CELL-SIGNALING PATHWAY	93
ATP-BINDING CASSETTE (ABC) DRUG TRANSPORTERS	93
<i>TABLE 37 OVARIAN CANCER: BIOMARKERS AS DRUG CANDIDATES</i>	94
OUTLOOK	96
CHAPTER 7 OVARIAN CANCER INCIDENCE	99
CANCER AND ITS GLOBAL IMPACT	99
<i>TABLE 38 GLOBAL CANCER INCIDENCE</i>	100
<i>TABLE 39 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)</i>	100
<i>FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)</i>	101
<i>TABLE 40 CANCER KEY FACTS</i>	103
THE FUTURE OF CANCER	103
<i>TABLE 41 INCREASE IN CANCER BURDEN: FACTORS</i>	104
OVARIAN CANCER INCIDENCE	105
<i>TABLE 42 OVARIAN CANCER INCIDENCE BY REGION, 2008</i>	106
<i>FIGURE 2 OVARIAN CANCER INCIDENCE BY REGION, 2008</i>	106
<i>TABLE 43 GLOBAL OVARIAN CANCER INCIDENCE, 2008</i>	106
<i>TABLE 44 ESTIMATED GLOBAL OVARIAN CANCER INCIDENCE, 2010-2018</i>	107
<i>FIGURE 3 ESTIMATED GLOBAL OVARIAN CANCER INCIDENCE, 2010-2018</i>	107
<i>TABLE 45 OVARIAN CANCER INCIDENCE BY LOCATION, 2008 (NUMBER OF CASES)</i>	108
<i>FIGURE 4 OVARIAN CANCER INCIDENCE BY LOCATION, 2008 (NUMBER OF CASES)</i>	108
NORTH AMERICA	109
<i>TABLE 46 ESTIMATED OVARIAN CANCER INCIDENCE IN NORTH AMERICA, 2010-2018</i>	109
<i>FIGURE 5 ESTIMATED OVARIAN CANCER INCIDENCE IN NORTH AMERICA, 2010-2018</i>	110
OVARIAN CANCER INCIDENCE IN UNITED STATES	110

TOPIC	PAGE NO.
<i>TABLE 47 OVARIAN CANCER - U.S. INCIDENCE, 2012</i>	110
<i>TABLE 48 NEW CASES AND DEATHS FROM OVARIAN CANCER IN THE U. S., 2013</i>	111
<i>FIGURE 6 NEW CASES AND DEATHS FROM OVARIAN CANCER IN THE U.S., 2013</i>	111
<i>TABLE 49 ESTIMATED OVARIAN CANCER INCIDENCE IN THE U.S., 2012-2018</i>	112
<i>FIGURE 7 ESTIMATED OVARIAN CANCER INCIDENCE IN THE U.S. 2012-2018</i>	112
<i>TABLE 50 OVARIAN CANCER: INCIDENCE AND MORTALITY IN UNITED STATES, 2009-2013</i>	112
<i>FIGURE 8 OVARIAN CANCER: INCIDENCE AND MORTALITY IN U.S., 2009-2013</i>	112
<i>TABLE 51 OVARIAN CANCER SURVIVAL RATES COMPARED TO OTHER CANCERS</i>	113
Survival and Stage	113
<i>TABLE 52 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008 (%)</i>	114
EUROPE AND OVARIAN CANCER	114
<i>TABLE 53 OVARIAN CANCER - EUROPEAN AGE-STANDARDIZED INCIDENCE RATES IN EU-27 COUNTRIES, 2008 ESTIMATES</i>	115
<i>FIGURE 9 OVARIAN CANCER EUROPEAN AGE-STANDARDIZED INCIDENCE IN EU-27 COUNTRIES, 2008 ESTIMATES</i>	115
<i>TABLE 54 ESTIMATED OVARIAN CANCER INCIDENCE IN EUROPE, 2012-2018</i>	116
<i>FIGURE 10 ESTIMATED OVARIAN CANCER: INCIDENCE IN EUROPE 2012-2018</i>	116
<i>TABLE 55 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE IN EUROPEAN UNION, 2008</i>	118
OVARIAN CANCER IN UK	119
<i>TABLE 56 HOW MANY WOMEN DIE FROM OVARIAN CANCER?</i>	119
<i>TABLE 57 OVARIAN CANCER - NUMBER OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008</i>	120
<i>TABLE 58 GYNECOLOGICAL CANCERS - NUMBER OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008</i>	120
<i>FIGURE 11 GYNECOLOGICAL CANCERS - NUMBERS OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008</i>	120
Trends	121
<i>TABLE 59 OVARIAN CANCER STATISTICS IN THE U.K., 2010</i>	121
<i>FIGURE 12 OVARIAN CANCER STATISTICS IN THE U.K., 2010</i>	122
THE MIDDLE EAST AND OVARIAN CANCER	122
OVARIAN CANCER AND CHINA	122
OVARIAN CANCER AND AUSTRALIA	122
OVARIAN CANCER AND INDIA	123
TYPES OF OVARIAN CANCERS AND INCIDENCE	124
PRIMARY PERITONEAL AND PRIMARY FALLOPIAN TUBE CANCERS	125
OVARIAN EPITHELIAL CANCER	125
<i>TABLE 60 PROGNOSIS FOR OVARIAN CANCER</i>	126
OVARIAN GERM CELL TUMORS	126
DYSGERMINOMAS	126
OVARIAN TUMORS OF LOW MALIGNANT POTENTIAL	126
SUMMARY	127
CHAPTER 8 MARKET	129
GLOBAL IVD MARKET	129
OVARIAN CANCER: DIAGNOSTIC TESTS	130

TOPIC	PAGE NO.
<i>TABLE 61 GLOBAL OVARIAN CANCER DIAGNOSTIC TESTS AND MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	130
<i>FIGURE 13 OVARIAN CANCER DIAGNOSTIC TESTS AND MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	130
GENETIC TESTING	131
SURGICAL BIOPSY	131
OVARIAN CANCER: CURRENT SCREENING PRACTICES	131
<i>TABLE 62 OVARIAN ABNORMALITIES</i>	131
THE FUTURE OF OVARIAN CANCER SCREENING	131
CURRENT BIOMARKER-BASED TESTS	132
TRANSVAGINAL SONOGRAPHY	132
Drawbacks	133
<i>TABLE 63 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	133
<i>FIGURE 14 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	133
<i>TABLE 64 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	134
<i>FIGURE 15 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	134
SERUM CA-125 IN COMBINATION WITH TRANSVAGINAL ULTRASOUND	135
PROTEOMICS	135
IMAGING TECHNIQUES	136
<i>TABLE 65 IMAGING TESTS</i>	136
BLOOD TESTS AND MARKET	136
<i>TABLE 66 OVARIAN CANCER - RISK TYPES</i>	136
<i>TABLE 67 OVARIAN CANCER - WOMEN WITH INCREASED RISK</i>	137
<i>TABLE 68 OVARIAN CANCER: INHERITED RISK DUE TO KNOWN GENETIC MUTATIONS</i>	137
OVARIAN CANCER TESTS AND MARKET DYNAMICS	138
<i>TABLE 69 GLOBAL MARKET FOR LAB TESTS FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	138
<i>FIGURE 16 GLOBAL MARKET FOR LAB TESTS FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	139
<i>TABLE 70 U.S. MARKET FOR LAB TESTS FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	139
<i>FIGURE 17 U.S. MARKET FOR LAB TESTS FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	139
CA-125 TEST MARKET	140
<i>TABLE 71 ELEVATED CA-125 LEVEL</i>	141
<i>TABLE 72 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, THROUGH 2018 (\$ MILLIONS)</i>	142
<i>FIGURE 18 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, 2012-2018 (\$ MILLIONS)</i>	142
<i>TABLE 73 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, THROUGH 2018 (\$ MILLIONS)</i>	143
<i>FIGURE 19 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, 2012-2018 (\$ MILLIONS)</i>	143
HE4 TEST MARKET	143

TOPIC	PAGE NO.
<i>TABLE 74 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, THROUGH 2018 (\$ MILLIONS)</i>	144
<i>FIGURE 20 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, 2012-2018</i>	144
<i>TABLE 75 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, THROUGH 2018 (\$ MILLIONS)</i>	145
<i>FIGURE 21 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, 2012-2018 (\$ MILLIONS)</i>	145
WHY THE HE4 TEST AND CA-125 COMBINED?	145
<i>TABLE 76 WHY HE4 AND CA-125 COMBINED?</i>	146
<i>TABLE 77 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, THROUGH 2018 (\$ MILLIONS)</i>	146
<i>FIGURE 22 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, 2012-2018 (\$ MILLIONS)</i>	146
<i>TABLE 78 UNITED STATES OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, THROUGH 2018 (\$ MILLIONS)</i>	147
<i>FIGURE 23 UNITED STATES OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, 2012-2018 (\$ MILLIONS)</i>	147
OVA1 BLOOD TEST AND MARKET	149
<i>TABLE 79 GLOBAL OVA1 MARKET, THROUGH 2018 (\$ MILLIONS)</i>	149
<i>FIGURE 24 GLOBAL OVA1 MARKET, 2011-2018 (\$ MILLIONS)</i>	150
Why OVA1?	151
OvaSure	151
OvaCheck	151
Onko-Sure	152
New Test	152
RECOMMENDATIONS FOR OVARIAN CANCER SCREENING	153
MOLECULAR DIAGNOSTICS MARKET	154
<i>TABLE 80 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	154
<i>FIGURE 25 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2012-2018 (\$ MILLIONS)</i>	154
ARRAYIT'S EARLY OVARIAN CANCER DIAGNOSTICTEST	155
<i>TABLE 81 GLOBAL MARKET FOR OVADX, THROUGH 2018 (\$ MILLIONS)</i>	155
<i>FIGURE 26 GLOBAL MARKET FOR OVADX, 2012-2018 (\$ MILLIONS)</i>	156
<i>TABLE 82 U.S. MARKET FOR OVADX, THROUGH 2018 (\$ MILLIONS)</i>	156
<i>FIGURE 27 U.S. MARKET FOR OVADX - SALES AND FORECAST 2012-2018 (\$ MILLIONS)</i>	157
PAP TESTS AND OVARIAN CANCERS	157
SURGERY MARKET	157
<i>TABLE 83 GLOBAL OVARIAN CANCER SURGERY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	158
<i>FIGURE 28 GLOBAL OVARIAN CANCER SURGERY MARKET, 2010-2018 (\$ MILLIONS)</i>	159
<i>TABLE 84 U.S. OVARIAN CANCER SURGERY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	159
<i>FIGURE 29 U.S. OVARIAN CANCER SURGERY MARKET, 2012-2018 (\$ MILLIONS)</i>	160
COMPUTED TOMOGRAPHY	160
<i>TABLE 85 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	160
<i>FIGURE 30 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	160

TOPIC	PAGE NO.
<i>TABLE 86 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)</i>	161
<i>FIGURE 31 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)</i>	161
MOLECULAR DIAGNOSTICS	162
CONCLUSIONS	162
CHAPTER 9 GLOBAL OVARIAN CANCER TREATMENT MARKET	165
OVARIAN CANCER: CURRENT SCENARIO	165
<i>TABLE 87 KEY HIGHLIGHTS OF THE THERAPEUTIC MARKET</i>	165
GLOBAL SPENDING ON MEDICINES	165
GLOBAL TREATMENTS AND FUTURE TRENDS	166
MARKET DYNAMICS	166
<i>TABLE 88 NEW LAUNCHES IN 2012</i>	166
CANCER TREATMENT MARKET	167
CANCER THERAPY: GOOD AND BAD	168
<i>TABLE 89 MAJOR PLAYERS</i>	168
CYTOTOXIC THERAPIES MARKET	169
<i>TABLE 90 CYTOTOXIC THERAPIES MARKET INDICATIONS</i>	169
<i>TABLE 91 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	169
<i>FIGURE 32 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	169
<i>TABLE 92 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	170
<i>FIGURE 33 U.S. CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)</i>	170
<i>TABLE 93 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	171
<i>FIGURE 34 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)</i>	172
<i>TABLE 94 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	172
<i>FIGURE 35 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)</i>	173
GLOBAL OVARIAN CHEMOTHERAPY CANCER MARKET	173
<i>TABLE 95 GLOBAL OVARIAN CANCER CHEMOTHERAPY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	173
<i>FIGURE 36 GLOBAL OVARIAN CANCER CHEMOTHERAPY MARKET, 2012-2018 (\$ MILLIONS)</i>	173
<i>TABLE 96 OVARIAN CANCER CHEMOTHERAPY MARKET IN KEY COUNTRIES THROUGH 2018 (\$ MILLIONS)</i>	174
<i>FIGURE 37 OVARIAN CANCER CHEMOTHERAPY MARKET IN KEY COUNTRIES, 2012-2018 (\$ MILLIONS)</i>	174
OVARIAN CANCER TREATMENT STRATEGIES: CURRENT TRENDS	175
CURRENT TREATMENT PRACTICES FOR OVARIAN CANCER: IMPACT ON THE MARKET	175
<i>TABLE 97 STANDARD INITIAL CHEMOTHERAPY</i>	176
<i>TABLE 98 DRUGS FOR RECURRENT OVARIAN CANCER</i>	177
<i>TABLE 99 HORMONAL THERAPY DRUGS</i>	177
CHEMOTHERAPY AND DRAWBACKS	177
Drugs Used in Chemotherapy	178
Paclitaxel	178
<i>TABLE 100 KEY OVARIAN CANCER DRUGS- SALES, 2010 (\$ MILLIONS)</i>	178
Carboplatin	178
<i>TABLE 101 CARBOPLATIN: SALES, THROUGH 2012 (\$ MILLIONS)</i>	179
Doxil	179

TOPIC	PAGE NO.
Taxotere/Docetaxel	179
<i>TABLE 102 TAXOTERE GLOBAL SALES AND FORECAST 2010-2012 (\$ MILLIONS)</i>	180
Cisplatin	180
Gemzar	180
<i>TABLE 103 GEMZAR REVENUE, 2010 AND 2011 (\$ MILLIONS)</i>	181
Future for Gemcitabine	181
Hycamtin	182
Navelbine	182
Carboplatin	182
TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY OVARIAN CANCER: MARKET ANALYSIS	182
<i>TABLE 104 DRUGS FOR REFRACTORY OVARIAN CANCER</i>	182
<i>TABLE 105 HORMONAL THERAPY DRUGS</i>	183
RADIATION THERAPY	183
CURRENT COMPETITION IN OVARIAN CANCER DRUGS	183
NEW MOLECULES	184
<i>TABLE 106 PROMISING MOLECULES</i>	184
Avastin	184
<i>TABLE 107 AVASTIN-REVENUES, THROUGH 2013 (\$ MILLIONS)</i>	185
<i>TABLE 108 AVASTIN-OVARIAN CANCER MARKET FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	186
Abagovomab	186
<i>TABLE 109 NEW MOLECULES - ESTIMATED SALES, 2018 (\$ MILLIONS)</i>	187
Pazopanib	187
Nintedanib	188
Opt-821	188
Paclical (Paclitaxel)	188
Opaxio	188
AMG 386	188
Vintafolide (EC145)	188
Karenitecin	189
Farletuzumab	189
FUTURE FOR OVARIAN CANCER MARKET	189
<i>TABLE 110 PROMISING BIOLOGIC DRUG TREATMENTS</i>	190
OVARIAN CANCER - COSTS AND MARKET OUTLOOK	190
MARKET OVERVIEW - GLOBAL PERSPECTIVES	191
THE PIPELINE - NEW RESEARCH AREAS	192
<i>TABLE 111 DRUG CATEGORIES IN DEVELOPMENT MOLECULES IN THE PIPELINE</i>	192
CONCLUSIONS: UNMET NEEDS	193
CHAPTER 10 PATENT LANDSCAPE	195
<i>TABLE 112 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2013</i>	195
<i>TABLE 113 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2014</i>	195
<i>TABLE 114 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2015</i>	196
<i>TABLE 115 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2016</i>	197
GLOBAL IMPACT OF PATENT EXPIRIES	197
PATENT LANDSCAPE	198
GEMZAR	199

TOPIC	PAGE NO.
<i>TABLE 116 OVARIAN CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY</i>	199
DOXIL	199
CISPLATIN	200
CHAPTER 11 LATEST NEWS AND DEVELOPMENTS	202
LILLY'S EARLY ONCOLOGY PIPELINE	202
LPATH AND DIAGNOSTICS	202
ROCHE	203
EARLY STAGE OVARIAN CANCER DIAGNOSTIC	204
NEW CHEMOTHERAPY STRATEGY EMERGES IN OVARIAN CANCER	204
Court Reaffirms Right of Myriad Genetics to Patent Genes	205
NANOTECHED RNA DRUG REDUCES OVARIAN CANCER TUMORS	206
VERASTEM LAUNCHES OVARIAN CANCER TRIAL	207
WORK ON GENETIC CAUSES OF PROSTATE, BREAST AND OVARIAN CANCER	207
OVARIAN CANCER VACCINE	208
NOVOTTF THERAPY	208
CHAPTER 12 SELECTED COMPANIES	210
ABBOTT LABORATORIES	210
AMGEN	210
APP PHARMACEUTICALS	210
ARRAYIT CORP.	211
ASTRAZENECA	211
BIONUMERIK PHARMACEUTICALS	211
BOEHRINGER INGELHEIM GMBH	212
BRISTOL-MYERS SQUIBB	212
CELL THERAPEUTICS, INC.	212
CHUGAI PHARMACEUTICAL	213
EISAI INC.	213
ELI LILLY AND COMPANY	213
ENDOCYTE	214
FUJIREBIO DIAGNOSTICS	214
GE HEALTHCARE	214
GLAXOSMITHKLINE	215
GOLD STANDARD DIAGNOSTICS	216
JOHNSON & JOHNSON	216
LPATH	217
MENARINI GROUP	217
MYRIAD GENETICS	217
NOVOCURE	218
OASMIA PHARMACEUTICAL	218
OPTIMER PHARMACEUTICALS	218
PFIZER	219
PROVISTA DIAGNOSTICS	219
RADIANT PHARMACEUTICALS	220
ROCHE DIAGNOSTICS	220
SANOFI	220

TOPIC	PAGE NO.
TAJ PHARMACEUTICALS	221
TELIK, INC.	221
TEVA PHARMACEUTICAL INDUSTRIES LTD.	221
VERMILLION	222
CHAPTER 13 REFERENCES	224

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 OVARIAN CANCER FACTS	9
TABLE 2 TYPES OF OVARIAN CANCERS	10
TABLE 3 OVARIAN TUMORS METASTASIS	11
TABLE 4 MAIN RISK FACTORS FOR OVARIAN CANCER	12
TABLE 5 HIGH-RISK FACTORS	12
TABLE 6 PREVENTIVE FACTORS	13
TABLE 7 OVARIAN CANCER SYMPTOMS	14
TABLE 8 HOW OVARIAN CANCER CAN PROGRESS	21
TABLE 9 COMMON HISTOLOGICAL SUBTYPES OF OVARIAN CANCERS	22
TABLE 10 OVARIAN CANCER ORIGINS	23
TABLE 11 MUTATED GENES IN HIGH-GRADE SEROUS OVARIAN CANCER	25
TABLE 12 GLOBAL PROGNOSTIC OVARIAN CANCER BIOMARKERS	28
TABLE 13 ACOG GUIDELINES 2002	30
TABLE 14 GENES IN TYPE I EPITHELIAL OVARIAN CANCER CELLS	34
TABLE 15 OVARIAN CANCER SYMPTOMS	38
TABLE 16 STAGES OF OVARIAN CANCER	42
TABLE 17 STAGING OF OVARIAN CANCER	43
TABLE 18 DIAGNOSTIC TESTS FOR OVARIAN CANCER	44
TABLE 19 TUMOR BIOMARKER-BASED TESTS FOR OVARIAN CANCER DIAGNOSIS	51
TABLE 20 TEST FEATURES OF ROMA	54
TABLE 21 OVADX FEATURES	56
TABLE 22 DRUGS FOR OVARIAN CANCER	65
TABLE 23 OTHER MAJOR THERAPEUTIC AGENTS	65
TABLE 24 CURRENT TREATMENT STRATEGY: OVARIAN CANCER	66
TABLE 25 CHEMOTHERAPEUTIC DRUGS FOR OVARIAN CANCER	69
TABLE 26 CHEMOTHERAPY ADMINISTRATION	70
TABLE 27 TREATMENT OPTIONS BY STAGE	72
TABLE 28 PIPELINE DRUG CLASSES	74
TABLE 29 OVARIAN CANCER DRUGS: DELIVERY TECHNOLOGIES	75
TABLE 30 OPTIMAL SURVEILLANCE STRATEGY	75
TABLE 31 TREATMENT PLAN FOR RECURRENT CANCER	76
TABLE 32 PLATINUM RESISTANCE	77
TABLE 33 REASONS FOR THE ONSET OF MDR	78
TABLE 34 DRUGS APPROVED FOR OVARIAN CANCER	84
TABLE 35 NEW OVARIAN CANCER DRUGS	85
TABLE 36 OVARIAN CANCER DRUGS IN CLINICAL TRIALS	86
TABLE 37 OVARIAN CANCER: BIOMARKERS AS DRUG CANDIDATES	94
TABLE 38 GLOBAL CANCER INCIDENCE	100
TABLE 39 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)	100
TABLE 40 CANCER KEY FACTS	103
TABLE 41 INCREASE IN CANCER BURDEN: FACTORS	104
TABLE 42 OVARIAN CANCER INCIDENCE BY REGION, 2008	106
TABLE 43 GLOBAL OVARIAN CANCER INCIDENCE, 2008	106
TABLE 44 ESTIMATED GLOBAL OVARIAN CANCER INCIDENCE, 2010-2018	107
TABLE 45 OVARIAN CANCER INCIDENCE BY LOCATION, 2008 (NUMBER OF CASES)	108

TABLE HEADING	PAGE NO.
TABLE 46 ESTIMATED OVARIAN CANCER INCIDENCE IN NORTH AMERICA, 2010-2018	109
TABLE 47 OVARIAN CANCER - U.S. INCIDENCE, 2012	110
TABLE 48 NEW CASES AND DEATHS FROM OVARIAN CANCER IN THE U. S., 2013	111
TABLE 49 ESTIMATED OVARIAN CANCER INCIDENCE IN THE U.S., 2012-2018	112
TABLE 50 OVARIAN CANCER: INCIDENCE AND MORTALITY IN UNITED STATES, 2009-2013	112
TABLE 51 OVARIAN CANCER SURVIVAL RATES COMPARED TO OTHER CANCERS	113
TABLE 52 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008 (%)	114
TABLE 53 OVARIAN CANCER - EUROPEAN AGE-STANDARDIZED INCIDENCE RATES IN EU-27 COUNTRIES, 2008 ESTIMATES	115
TABLE 54 ESTIMATED OVARIAN CANCER INCIDENCE IN EUROPE, 2012-2018	116
TABLE 55 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE IN EUROPEAN UNION, 2008	118
TABLE 56 HOW MANY WOMEN DIE FROM OVARIAN CANCER?	119
TABLE 57 OVARIAN CANCER - NUMBER OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008	120
TABLE 58 GYNECOLOGICAL CANCERS - NUMBER OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008	120
TABLE 59 OVARIAN CANCER STATISTICS IN THE U.K., 2010	121
TABLE 60 PROGNOSIS FOR OVARIAN CANCER	126
TABLE 61 GLOBAL OVARIAN CANCER DIAGNOSTIC TESTS AND MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	130
TABLE 62 OVARIAN ABNORMALITIES	131
TABLE 63 GLOBAL MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	133
TABLE 64 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	134
TABLE 65 IMAGING TESTS	136
TABLE 66 OVARIAN CANCER - RISK TYPES	136
TABLE 67 OVARIAN CANCER - WOMEN WITH INCREASED RISK	137
TABLE 68 OVARIAN CANCER: INHERITED RISK DUE TO KNOWN GENETIC MUTATIONS	137
TABLE 69 GLOBAL MARKET FOR LAB TESTS FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	138
TABLE 70 U.S. MARKET FOR LAB TESTS FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	139
TABLE 71 ELEVATED CA-125 LEVEL	141
TABLE 72 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, THROUGH 2018 (\$ MILLIONS)	142
TABLE 73 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, THROUGH 2018 (\$ MILLIONS)	143
TABLE 74 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, THROUGH 2018 (\$ MILLIONS)	144
TABLE 75 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, THROUGH 2018 (\$ MILLIONS)	145
TABLE 76 WHY HE4 AND CA-125 COMBINED?	146
TABLE 77 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, THROUGH 2018 (\$ MILLIONS)	146
TABLE 78 UNITED STATES OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, THROUGH 2018 (\$ MILLIONS)	147
TABLE 79 GLOBAL OVA1 MARKET, THROUGH 2018 (\$ MILLIONS)	149

TABLE HEADING	PAGE NO.
TABLE 80 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)	154
TABLE 81 GLOBAL MARKET FOR OVADX, THROUGH 2018 (\$ MILLIONS)	155
TABLE 82 U.S. MARKET FOR OVADX, THROUGH 2018 (\$ MILLIONS)	156
TABLE 83 GLOBAL OVARIAN CANCER SURGERY MARKET, THROUGH 2018 (\$ MILLIONS)	158
TABLE 84 U.S. OVARIAN CANCER SURGERY MARKET, THROUGH 2018 (\$ MILLIONS)	159
TABLE 85 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	160
TABLE 86 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, THROUGH 2018 (\$ MILLIONS)	161
TABLE 87 KEY HIGHLIGHTS OF THE THERAPEUTIC MARKET	165
TABLE 88 NEW LAUNCHES IN 2012	166
TABLE 89 MAJOR PLAYERS	168
TABLE 90 CYTOTOXIC THERAPIES MARKET INDICATIONS	169
TABLE 91 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	169
TABLE 92 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	170
TABLE 93 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	171
TABLE 94 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	172
TABLE 95 GLOBAL OVARIAN CANCER CHEMOTHERAPY MARKET, THROUGH 2018 (\$ MILLIONS)	173
TABLE 96 OVARIAN CANCER CHEMOTHERAPY MARKET IN KEY COUNTRIES THROUGH 2018 (\$ MILLIONS)	174
TABLE 97 STANDARD INITIAL CHEMOTHERAPY	176
TABLE 98 DRUGS FOR RECURRENT OVARIAN CANCER	177
TABLE 99 HORMONAL THERAPY DRUGS	177
TABLE 100 KEY OVARIAN CANCER DRUGS- SALES, 2010 (\$ MILLIONS)	178
TABLE 101 CARBOPLATIN: SALES, THROUGH 2012 (\$ MILLIONS)	179
TABLE 102 TAXOTERE GLOBAL SALES AND FORECAST 2010-2012 (\$ MILLIONS)	180
TABLE 103 GEMZAR REVENUE, 2010 AND 2011 (\$ MILLIONS)	181
TABLE 104 DRUGS FOR REFRACTORY OVARIAN CANCER	182
TABLE 105 HORMONAL THERAPY DRUGS	183
TABLE 106 PROMISING MOLECULES	184
TABLE 107 AVASTIN-REVENUES, THROUGH 2013 (\$ MILLIONS)	185
TABLE 108 AVASTIN-OVARIAN CANCER MARKET FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)	186
TABLE 109 NEW MOLECULES - ESTIMATED SALES, 2018 (\$ MILLIONS)	187
TABLE 110 PROMISING BIOLOGIC DRUG TREATMENTS	190
TABLE 111 DRUG CATEGORIES IN DEVELOPMENT MOLECULES IN THE PIPELINE	192
TABLE 112 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2013	195
TABLE 113 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2014	195
TABLE 114 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2015	196
TABLE 115 DRUGS SCHEDULED TO LOSE U.S. MARKET PROTECTION, 2016	197
TABLE 116 OVARIAN CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY	199

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, 2012-2018 (\$ MILLIONS)	7
FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)	101
FIGURE 2 OVARIAN CANCER INCIDENCE BY REGION, 2008	106
FIGURE 3 ESTIMATED GLOBAL OVARIAN CANCER INCIDENCE, 2010-2018	107
FIGURE 4 OVARIAN CANCER INCIDENCE BY LOCATION, 2008 (NUMBER OF CASES)	108
FIGURE 5 ESTIMATED OVARIAN CANCER INCIDENCE IN NORTH AMERICA, 2010-2018	110
FIGURE 6 NEW CASES AND DEATHS FROM OVARIAN CANCER IN THE U.S., 2013	111
FIGURE 7 ESTIMATED OVARIAN CANCER INCIDENCE IN THE U.S. 2012-2018	112
FIGURE 8 OVARIAN CANCER: INCIDENCE AND MORTALITY IN U.S., 2009-2013	112
FIGURE 9 OVARIAN CANCER EUROPEAN AGE-STANDARDIZED INCIDENCE IN EU-27 COUNTRIES, 2008 ESTIMATES	115
FIGURE 10 ESTIMATED OVARIAN CANCER: INCIDENCE IN EUROPE 2012-2018	116
FIGURE 11 GYNECOLOGICAL CANCERS - NUMBERS OF NEW CASES PER 100,000 POPULATION IN THE U.K., 2008	120
FIGURE 12 OVARIAN CANCER STATISTICS IN THE U.K., 2010	122
FIGURE 13 OVARIAN CANCER DIAGNOSTIC TESTS AND MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	130
FIGURE 14 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	133
FIGURE 15 U.S. MARKET FOR TRANSVAGINAL ULTRASOUND IN OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	134
FIGURE 16 GLOBAL MARKET FOR LAB TESTS FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	139
FIGURE 17 U.S. MARKET FOR LAB TESTS FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	139
FIGURE 18 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, 2012-2018 (\$ MILLIONS)	142
FIGURE 19 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR CA-125, 2012-2018 (\$ MILLIONS)	143
FIGURE 20 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, 2012-2018	144
FIGURE 21 U.S. OVARIAN CANCER DIAGNOSTIC MARKET FOR THE HE4 TEST, 2012-2018 (\$ MILLIONS)	145
FIGURE 22 GLOBAL OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, 2012-2018 (\$ MILLIONS)	146
FIGURE 23 UNITED STATES OVARIAN CANCER DIAGNOSTIC MARKET FOR THE ROMA TEST, 2012-2018 (\$ MILLIONS)	147
FIGURE 24 GLOBAL OVA1 MARKET, 2011-2018 (\$ MILLIONS)	150
FIGURE 25 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2012-2018 (\$ MILLIONS)	154
FIGURE 26 GLOBAL MARKET FOR OVADX, 2012-2018 (\$ MILLIONS)	156
FIGURE 27 U.S. MARKET FOR OVADX - SALES AND FORECAST 2012-2018 (\$ MILLIONS)	157
FIGURE 28 GLOBAL OVARIAN CANCER SURGERY MARKET, 2010-2018 (\$ MILLIONS)	159
FIGURE 29 U.S. OVARIAN CANCER SURGERY MARKET, 2012-2018 (\$ MILLIONS)	160
FIGURE 30 GLOBAL COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	160
FIGURE 31 U.S. COMPUTED TOMOGRAPHY IMAGING MARKET FOR OVARIAN CANCER, 2012-2018 (\$ MILLIONS)	161
FIGURE 32 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	169

FIGURE TITLE	PAGE NO.
FIGURE 33 U.S. CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)	170
FIGURE 34 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)	172
FIGURE 35 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)	173
FIGURE 36 GLOBAL OVARIAN CANCER CHEMOTHERAPY MARKET, 2012-2018 (\$ MILLIONS)	173
FIGURE 37 OVARIAN CANCER CHEMOTHERAPY MARKET IN KEY COUNTRIES, 2012-2018 (\$ MILLIONS)	174